Clinical Trial Update: Expanded Access to Venetoclax

View source ↗

Summary

Expanded access to venetoclax is being offered for multiple hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, AML, and other indica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Amyloidosis
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Plasma Cell Leukemia

Drugs mentioned

• Venclexta (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma | Status: AVAILABLE